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Correspondence and RepliesTelehealth: The future is now in allergy
practiceWe read with interest the Editorial by Portnoy et al,1 where the
authors, in the face of the current pandemic, very elegantly
summarize the main advantages and limitations of virtual ap-
pointments. Telemedicine (TM) has the potential to help enabling
patients to get the supportive care they need, and the use of this
tool is increasing.2 We agree with the authors that a pandemic
is an unfortunate occurrence but it is also an opportunity to set
up an infrastructure for providing care using TM, which can
continue to be used in the future to provide convenient and
cost-effective care to patients.1 TM has been successfully applied
to several respiratory conditions,3 and it can be an alternative to
traditional in-person visits for the treatment and management of
asthma.4
Worldwide coronavirus disease-2019 (COVID-19) brought a
lot of challenges in health care. In our country, the state of
emergency was declared on March 19, 2020, bringing strict
measures to nonurgent patient inflow in our hospital. Within a
pandemic risk-stratified context, knowing that allergic conditions
can bemisinterpreted or exacerbated by viral infections and social
distancing might increase anxiety, telehealth was considered as
an option to face-to-face contacts. For the first time, in 2 weeks,
real-time video appointments were implemented in our allergy
center.
Patients were invited to be consulted in virtual visits, including
first appointments (12% of the total). We noted an increasing
agreement to virtual visits (Figure 1), followed by a decrease
when emergency state was over on May 2. For these consulta-
tions, patients only had to have internet connection and a smart-
phone, tablet, or computer with a camera and microphone. All
the prescriptions and treatment plans were also sent virtually.
When indicated we still received the more severe patients as in-
person visits, in particular patients with specific needs, including
desensitization to chemotherapy.
To assess satisfaction and willingness to repeat or recommend
virtual appointments, we conducted 2 surveys, one for patientsFIGURE 1. Distribution of in-person and real-time video-virtual visits at the A
(10th week). The virtual visits were implemented in the 14th week.with asthma (n 5 40) who had participated in virtual
consultations during this pandemic (with the collaboration of
the Portuguese Association of Asthmatics) and another one for
the allergy specialists of our center (n 5 21).
In summary, communication between patients and doctors was
not considered to be compromised in virtual appointments (>92%
agreement in both surveys). Most patients rated the virtual visit as
good/very good (93%). Ninety-five percent of the providers
considered that their performance was not affected, but 43%
had some difficulties in the management of their patients, mainly
related to the lack of physical examination. Seventy percent of
patients would adhere to these appointments outside COVID-19,
and 93% would recommend it to their family and friends. Doctors
consider that this way of practicing medicine has a future in our
health care system(93%), benefitingmild-to-severe patients (81%),
as well as those living far away from the hospital (19%). Less than
5% of the patients needed to be referred to do in-person visits.
Telemedicine is an already validated tool.1-4 The COVID-19
pandemic allowed us to implement telehealth-focused processes
to provide safe and convenient patient care, and both patients
and allergists seem willing to continue to use it.5
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